Fortrea Holdings (FTRE) Share-based Compensation (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Share-based Compensation came in at $12.6 million in Q2 2026, down 44.49% YoY from $22.7 million in Q2 2025, and up 10.53% on a QoQ basis from $11.4 million in Q1 2026.
Fortrea Holdings (FTRE) Share-based Compensation (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Share-based Compensation data on file, last reported at $12.6 million in Q2 2026.
- Quarterly Share-based Compensation fell 44.49% year-over-year to $12.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $61.1 million (down 6.86% YoY) and the FY2025 annual result came in at $74.4 million, up 27.4% from the prior year.
- Share-based Compensation advanced to $12.6 million in Q2 2026, from $11.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $22.7 million in Q2 2025 to a low of $5.8 million in Q4 2022.
- A 5-year average of $13.2 million and a median of $13.8 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation jumped 167.24% — and 2026, when it sank 44.49%.
- Tracing FTRE's Share-based Compensation over 5 years: stood at $5.8 million in 2022, then jumped by 167.24% to $15.5 million in 2023, then declined by 1.29% to $15.3 million in 2024, then decreased by 3.27% to $14.8 million in 2025, then retreated by 14.86% to $12.6 million in 2026.
- The last three Share-based Compensation figures came in at $12.6 million (Q2 2026), $11.4 million (Q1 2026), and $14.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn | 12.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.60 Mn |
| Jun 30, 2026 | 12.60 Mn |
| Mar 31, 2026 | 11.40 Mn |
| Mar 31, 2026 | 11.40 Mn |
| Dec 31, 2025 | 14.80 Mn |
| Dec 31, 2025 | 14.80 Mn |
| Sep 30, 2025 | 22.30 Mn |
| Sep 30, 2025 | 22.30 Mn |
| Jun 30, 2025 | 22.70 Mn |
| Jun 30, 2025 | 22.70 Mn |
| Mar 31, 2025 | 14.60 Mn |
| Mar 31, 2025 | 14.60 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Sep 30, 2024 | 13.00 Mn |
| Sep 30, 2024 | 13.00 Mn |
| Jun 30, 2024 | 15.00 Mn |
| Jun 30, 2024 | 15.00 Mn |
| Mar 31, 2024 | 15.10 Mn |
| Mar 31, 2024 | 15.10 Mn |